Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
April 2018
-
Press Release
Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation
Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World… -
Press Release
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
Post-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…
March 2018
-
Press Release
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,… -
Press Release
AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening… -
Key Release
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term… -
Key Release
Novartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren
Preis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf… -
Press Release
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a… -
Press Release
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate… -
Press Release
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA… -
Press Release
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development… -
Press Release
AveXis Enters into Licensing Agreement with Genethon
Includes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today… -
Key Release
Novartis announces changes to the Executive Committee to support strategic priorities
Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…